J&J: Crohn's disease drug shows encouraging results
(CercleFinance.com) - New phase 3b data has showed that two-thirds of patients with Crohn's disease achieved clinical remission after two doses of Janssen's ustekinumab, the J&J unit said on Friday.
At week 16, 79% of patients with moderately to severely active Crohn's disease achieved clinical response and 67% were in clinical remission after receiving one intravenous dose, followed by one subcutaneous dose of the drug, Janssen said.
The analysis, which includes 500 participants, is the first study to explore a treatment strategy using endoscopy to guide dose adjustment.
Copyright (c) 2020 CercleFinance.com. All rights reserved.